C.R. Bard Inc. (NYSE:BCR)‘s stock had its “hold” rating reiterated by research analysts at Jefferies Group in a research note issued on Tuesday. They currently have a $237.00 price target on the stock. Jefferies Group’s target price would indicate a potential upside of 4.27% from the stock’s previous close.
A number of other analysts also recently issued reports on the stock. Wells Fargo & Co. upgraded shares of C.R. Bard from a “market perform” rating to an “outperform” rating in a report on Friday, September 16th. Evercore ISI initiated coverage on shares of C.R. Bard in a report on Thursday, September 15th. They issued a “buy” rating and a $235.00 price objective on the stock. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Morgan Stanley reissued a “hold” rating and issued a $240.00 target price on shares of C.R. Bard in a research note on Thursday, July 28th. Finally, Leerink Swann reissued a “market perform” rating and issued a $233.00 target price (down from $240.00) on shares of C.R. Bard in a research note on Thursday, July 28th. Thirteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $233.00.
C.R. Bard (NYSE:BCR) opened at 227.30 on Tuesday. The stock has a 50 day moving average of $221.43 and a 200-day moving average of $218.92. The firm has a market cap of $16.70 billion, a PE ratio of 52.86 and a beta of 0.57. C.R. Bard has a 52 week low of $172.21 and a 52 week high of $239.43.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.07. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The company had revenue of $931.50 million for the quarter, compared to the consensus estimate of $915.22 million. During the same period last year, the company earned $2.27 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. Analysts expect that C.R. Bard will post $10.17 earnings per share for the current year.
In related news, Chairman Timothy M. Ring sold 110,000 shares of the business’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $228.96, for a total value of $25,185,600.00. Following the completion of the transaction, the chairman now owns 96,030 shares of the company’s stock, valued at $21,987,028.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Betty D. Larson sold 4,032 shares of the business’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $225.33, for a total value of $908,530.56. Following the completion of the transaction, the vice president now directly owns 10,298 shares of the company’s stock, valued at approximately $2,320,448.34. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of BCR. Standard Life Investments LTD bought a new position in C.R. Bard during the second quarter worth approximately $241,642,000. JPMorgan Chase & Co. increased its position in C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock worth $135,290,000 after buying an additional 520,319 shares during the period. Fundsmith LLP increased its position in C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock worth $516,220,000 after buying an additional 435,595 shares during the period. Bank of Montreal Can bought a new position in C.R. Bard during the second quarter worth approximately $96,292,000. Finally, Vanguard Group Inc. increased its position in C.R. Bard by 4.7% in the second quarter. Vanguard Group Inc. now owns 7,413,815 shares of the company’s stock worth $1,743,433,000 after buying an additional 335,276 shares during the period. 87.90% of the stock is owned by institutional investors and hedge funds.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.